上海医药(601607.SH)：硫酸沙丁胺醇注射液通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Salbutamol Sulfate Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Salbutamol Sulfate Injection is primarily used for treating bronchial asthma or wheezing bronchitis and other respiratory diseases associated with bronchospasm [1]